-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

Benzinga·07/23/2026 18:36:12
Listen to the news
JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $425.